Financing channel feed – Endpoints News

Financing channel feed

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

6 years ago

The big C: The dealmakers, dollars and diseases that have transformed the Chinese biopharma market

6 years ago

Flagship’s Sigilon grabs $80M to bring Robert Langer cell therapy tech into the clinic

6 years ago

Partnered with Gilead and Sanofi, protein degradation specialist Nurix bags $120M to chart its own clinical path

6 years ago

Harbour BioMed nets $75M in Series B+ as first global trial gets underway

6 years ago

Is HKEX ready to return to biotech business? InnoCare tests waters with hopes to fetch $257M in IPO

6 years ago

Silverback Therapeutics gets $78M boost to 'reconceptualize' antibody-drug conjugates

6 years ago

J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO

6 years ago

Israel’s Arkin Holdings launches second biotech fund, worth $140 million

6 years ago

Versant woos MorphoSys' ex-CSO to its booming discovery engine, with big plans for new startups

6 years ago

Chinese biotech bags $50M+ for I/O, autoimmune work, starting with ALK5 inhibitor

6 years ago

Neil Woodford in the game to buy back his former unlisted portfolio that's proving hard to sell — reports

6 years ago

Trifecta of clinical stage biotechs unveil IPO plans, braving Wall Street's coronavirus panic

6 years ago

Mitsubishi joins Eisai, 3SBio's bet on multispecific antibodies, upping Numab's Series B haul to $23M+

6 years ago

After a trendsetting role in global biotech venture investing, David Mott parts ways with NEA

6 years ago

Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes

6 years ago

Hear hear! Ear gene therapy player Akouos draws $105M in fresh capital

6 years ago

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

6 years ago

Woodford who? TCR-focused Immunocore soldiers on with $130M+ B round

6 years ago

Ex nihilo: Takeda leads $100M+ round to fund biotech's sneak attack on tumors, propelling new IL-2, CTLA-4 drugs to clinic

6 years ago

Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO

6 years ago

Tying basic science to spinouts, Dana-Farber debuts sister funds totaling $126M with MPM Capital

6 years ago

SoftBank's newest, $165M biotech investment looks for infectious traces in the blood

6 years ago

Animal health vet Juergen Horn makes new antibody play for pets, raking $15M in Series A haul

6 years ago

First page Previous page 102 103 104105106 107 108 Next page Last page